The figure looks clean and informative. Here's the full interpretation of what the MI analysis reveals:

---

## Multiple Imputation vs Complete-Case Analysis

### What drives the 315 exclusions?

The missingness is **not random** in one important way: excluded patients have a **median follow-up of only 1 year** vs 5 years for included patients (p<0.0001). This is a classic **Missing At Random (MAR)** pattern — patients who dropped out early simply hadn't had labs collected yet. The good news: their **event rate is nearly identical** (3.5% vs 3.8%, p=0.91), so the exclusions are not selectively removing high-risk patients.

The dominant driver of exclusions is **T2DM missingness (21%)**, followed by AST/GGT (13% each, highly correlated — same lab panel). Liver stiffness is almost complete (only 13 missing, 1%).

### Results: MI changes very little

| Variable | CC HR | MI HR | Change | FMI |
|---|---|---|---|---|
| Liver stiffness (kPa) | 1.137 | 1.117 | −0.020 | 0.001 |
| AST (U/L) | 1.022 | 1.016 | −0.006 | 0.001 |
| GGT (U/L) | 1.002 | 1.002 | 0.000 | 0.001 |
| Age (years) | 1.053 | 1.043 | −0.010 | 0.000 |
| T2DM | 0.943 | 0.943 | 0.000 | 0.002 |

**FMI (Fraction of Missing Information) < 0.01 for all variables** — this is the key diagnostic. FMI quantifies how much of the uncertainty in each HR estimate is attributable to the missing data. Values this close to zero mean the 315 excluded patients contribute essentially no additional information that changes the conclusions.

### One notable change: GGT crosses significance

Under MI (n=1,253), **GGT becomes nominally significant** (p=0.030, *) whereas it was non-significant in the complete-case analysis (p=0.102). This is because MI recovers 11 additional events from the 315 excluded patients, slightly increasing statistical power. However, the HR itself is unchanged (1.002), so this is a **power effect, not a bias correction**.

### Why the HRs shift slightly downward

The excluded patients are ~4 years older (median 59 vs 55) but have similar liver stiffness. When they are included via MI, the model adjusts for this age enrichment, slightly attenuating the liver stiffness HR (1.137 → 1.117) and age HR (1.053 → 1.043). Both remain highly significant and clinically meaningful.

### Bottom line

The complete-case analysis is **robust**. The MAR assumption is plausible (missingness explained by short follow-up, not by outcome), FMI is negligible for all covariates, and no conclusions change. The main practical benefit of MI here would be the modest gain in power for GGT — but given the borderline effect size (HR 1.002/U/L), this is unlikely to be clinically meaningful.